| Bioactivity | Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)[1][2]. | ||||||||||||
| Name | Bcl-xL antagonist 2 | ||||||||||||
| CAS | 1235032-75-3 | ||||||||||||
| Formula | C21H16N4O3S2 | ||||||||||||
| Molar Mass | 436.51 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Bcl-xL antagonist 2
CAS: 1235032-75-3 F: C21H16N4O3S2 W: 436.51
Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.